Synapse - Works

Results (13087)

A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i)

Meeting Abstract

Mascarenhas, J. O.; Borate, U.; Bose, P.; Byrd, J. C.; Garcia, J. S.; Grunwald, M. R.; Hobbs, G. S.; Hoffman, R.; Kuykendall, A. T.; Mesa, R. A.; more...
Blood (2024)

Fulltext@MSK | Save

POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib

Meeting Abstract

Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; more...
Blood (2024)

Fulltext@MSK | Save

Practice patterns inform patient-centered approaches for the integration of BTK inhibitors in frontline mantle cell lymphoma

Meeting Abstract

Graham, T.; Ackbarali, T.; Kumar, A.; Matasar, M.
Blood (2024)

Fulltext@MSK | Save

Characterization of skin response in patients with mycosis fungoides and sezary syndrome treated with mogamulizumab: A retrospective, real world cohort

Meeting Abstract

Christensen, R.; Stuver, R.; Dusza, S.; Epstein-Peterson, Z. D.; Ghione, P.; Horwitz, S.; Johnson, W. T.; Moskowitz, A.; Myskowski, P.; Pulitzer, M.; more...
Blood (2024)

Fulltext@MSK | Save

Treatment patterns of immunoglobulin replacement therapy among patients with multiple myeloma in the United States: A real-world analysis

Meeting Abstract

Ida, F.; Ramakrishna, B.; Nasserinejad, K.; Radu, A.; Lawo, J. P.; Zhang, X.; Gardiner, D.; Yoon, L.; Shen, J.; Dabrowski, E. C.; more...
Blood (2024)

Fulltext@MSK | Save

Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma

Meeting Abstract

Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood (2024)

Fulltext@MSK | Save

Defining the rates of cytokine release syndrome associated with talquetamab step-up doses

Meeting Abstract

Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
Blood (2024)

Fulltext@MSK | Save

Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies

Meeting Abstract

Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
Blood (2024)

Fulltext@MSK | Save

Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma

Meeting Abstract

Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
Blood (2024)

Fulltext@MSK | Save

Trial in progress: An open-label clinical trial of RVU120 as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

Meeting Abstract

Kuklik, R.; Falkowski, A.; Zaroogian, Z.; Mazan, M.; Szymula, A.; Wilkinson, G.; Adamczyk, E.; Woznicki, J.; Micek, M.; Coelho, D.; more...
Blood (2024)

Fulltext@MSK | Save